Widely used:Recently Viewed
Clear AllValue Research Rating
Quality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
₹15,935 Cr
P/E Ratio
8.54
P/B Ratio
2.19
Industry P/E
36.27
Debt to Equity
0.06
ROE
25.88 %
ROCE
30.08 %
Div. Yield
1.07 %
Book Value
406.58
EPS
104.13
CFO
₹4,506.37 Cr
EBITDA
₹6,991.30 Cr
Net Profit
₹5,275.14 Cr
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Natco Pharma
| -35.90 | 7.15 | -29.24 | -10.95 | 4.24 | 7.31 | 8.65 |
|
BSE Healthcare
| -7.27 | -1.01 | -0.76 | 19.87 | 19.29 | 22.12 | 9.77 |
|
BSE Mid Cap
| -8.32 | 0.34 | -0.44 | 3.84 | 19.86 | 29.98 | 15.08 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Natco Pharma
| 69.52 | 44.46 | -37.92 | -6.48 | 55.58 | -14.53 | -31.05 |
|
BSE Mid Cap
| 25.84 | 45.53 | 1.38 | 39.18 | 19.87 | -3.05 | -13.31 |
|
BSE Healthcare
| 43.09 | 36.97 | -12.10 | 20.87 | 61.45 | -3.55 | -5.89 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | P/E Ratio | ROE |
|---|---|---|---|---|
| 1,360.70 | 38,348.27 | -- | -15.04 | |
| 625.65 | 33,724.85 | 94.12 | 8.33 | |
| 216.25 | 28,636.16 | 736.15 | 0.67 | |
| 1,143.20 | 29,103.14 | 104.23 | 13.86 |
From past growth to future prosperity
6 min read•By Rajan Gulati
Three mid caps that are up for easy grabs
5 min read•By Yash Rohra
4 min read•By Rajan Gulati
1 min read•By Research Desk
NATCO Pharma Limited, a pharmaceutical company, develops, manufactures, and markets finished dosage formulations and active pharmaceutical ingredients (APIs). The company offers formulations in various therapeutic areas, including cancers of blood,... liver, kidney, lung, brain, breast, ovary, etc.; and APIs in various categories, such as oncology, central nervous system, pain management, and CV care. It also offers orthopedic products comprising bisphosphonates, which are oral and injectable drugs; and gastroenterology products consisting of novel drugs for chronic hepatitis-B and hepatitis-C, as well as contract manufacturing services. In addition, the company provides cardiology and diabetology products for the treatment of hypertension, stable angina, and CHF. Additionally, it offers agro chemicals and biological pest management solutions for management of insects, diseases, and weeds across a range of crops. It markets its products in approximately 50 countries. NATCO Pharma Limited was incorporated in 1981 and is headquartered in Hyderabad, India. Read more
Incorporated
1981
Chairman
V C Nannapaneni
Managing Director
V C Nannapaneni
Group
Natco
Headquarters
Hyderabad, Telangana
Website
Looking for more details about Natco Pharma Ltd.’s IPO? Explore our IPO Details page.
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Natco Pharma Ltd stood at ₹ 8,245 Cr as on 31-Dec-24
The share price of Natco Pharma Ltd is ₹889.25 (NSE) and ₹889.65 (BSE) as of 25-Apr-2025 IST. Natco Pharma Ltd has given a return of 4.24% in the last 3 years.
Natco Pharma Ltd has a market capitalisation of ₹ 15,935 Cr as on 25-Apr-2025. As per Value Research classification, it is a Mid Cap company.
The P/B ratio of Natco Pharma Ltd is 2.19 times as on 25-Apr-2025, a 37% discount to its peers’ median range of 3.50 times.
The P/E ratio of Natco Pharma Ltd is 8.54 times as on 25-Apr-2025, a 76% discount to its peers’ median range of 36.27 times.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Natco Pharma Ltd and enter the required number of quantities and click on buy to purchase the shares of Natco Pharma Ltd.
NATCO Pharma Limited, a pharmaceutical company, develops, manufactures, and markets finished dosage formulations and active pharmaceutical ingredients (APIs). The company offers formulations in various therapeutic areas, including cancers of blood, liver, kidney, lung, brain, breast, ovary, etc.; and APIs in various categories, such as oncology, central nervous system, pain management, and CV care. It also offers orthopedic products comprising bisphosphonates, which are oral and injectable drugs; and gastroenterology products consisting of novel drugs for chronic hepatitis-B and hepatitis-C, as well as contract manufacturing services. In addition, the company provides cardiology and diabetology products for the treatment of hypertension, stable angina, and CHF. Additionally, it offers agro chemicals and biological pest management solutions for management of insects, diseases, and weeds across a range of crops. It markets its products in approximately 50 countries. NATCO Pharma Limited was incorporated in 1981 and is headquartered in Hyderabad, India.
The prominent promoters of Natco Pharma Ltd. are
| Name of promoters | Holding percentage |
|---|---|
|
V C NANNAPANENI |
15.66%
|
|
TIME CAP PHARMA LABS PRIVATE LIMITED |
9.59%
|
|
VENKATA SATYA SWATHI KANTAMANI |
8.9%
|
|
NATSOFT INFORMATION SYSTEMS PVT LTD |
8.81%
|
The chairman of the company is V C Nannapaneni, and the managing director is V C Nannapaneni.
There is no promoter pledging in Natco Pharma Ltd.
Some of the close peers are:
| Company | Market Cap(₹ Cr) |
|---|---|
|
38,348
|
|
|
33,725
|
|
|
29,103
|
|
|
28,636
|
| Natco Pharma Ltd. | Ratios |
|---|---|
|
Return on equity(%)
|
28.69
|
|
Operating margin(%)
|
45.66
|
|
Net Margin(%)
|
40.45
|
|
Dividend yield(%)
|
1.07
|
Yes, TTM profit after tax of Natco Pharma Ltd was ₹1,865 Cr.
₹-13.60
(
